Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | IL1RN | P18510 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1546612 | 0.98 | POLB (0.76) | POLBTSHRCYP3A4HSD17B10KDM4E | |
| SCHEMBL1647757 | 0.85 | POLB (0.88) | POLBTSHRCYP3A4HSD17B10KDM4E | |
| SCHEMBL1708867 | 0.85 | TSHR (1.00) | POLBTSHRCYP3A4HSD17B10KDM4E | |
| SCHEMBL4718657 | 0.84 | CYP3A4 (1.00) | TSHRCYP3A4HSD17B10KDM4EALDH1A1 | |
| SCHEMBL11825142 | 0.84 | TSHR (0.72) | POLBTSHRCYP3A4HSD17B10PKM | |
| SCHEMBL4717672 | 0.84 | TSHR (0.72) | POLBTSHRCYP3A4HSD17B10KDM4E | |
| SCHEMBL11178443 | 0.84 | CYP3A4 (1.00) | TSHRCYP3A4HSD17B10KDM4EALDH1A1 | |
| SCHEMBL3921818 | 0.83 | TSHR (0.97) | POLBTSHRCYP3A4HSD17B10KDM4E | |
| SCHEMBL1647455 | 0.83 | GLA (0.64) | POLBTSHRCYP3A4HSD17B10KDM4E | |
| SCHEMBL4469033 | 0.82 | SERPINE1 (0.72) | POLBTSHRCYP3A4HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104352492-A | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient | MSD KK | 2015-02-18 | — | — | CN | disclosed |
| EP-2280001-B1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD KK (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8420823-B2 | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient | MSD K.K. (JP) | 2013-04-16 | — | — | US | disclosed |
| EP-2280001-A1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-02-02 | — | — | EP | disclosed |
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD K.K. (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| EP-1615904-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | AstraZeneca AB (SE) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092135-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA (SE) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | ELOVL1, ELOVL6, ELOVL3 | POLB 3156/4885TSHR 3094/4885CYP3A4 984/4885 |
| US-20070021606-A1 | Therapeutic compounds | GRIN1, GRIN3A, GRM2 | POLB 3790/4885TSHR 685/4885CYP3A4 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.